◀ Back to HLA-DRB1

HDAC2 — HLA-DRB1

Text-mined interactions from Literome

Wang et al., J Immunol 2005 : However, mycobacterial infection or TLR2 stimulation up-regulated expression of mammalian Sin3A, a corepressor that is required for MHC class II repression by HDAC
Singh et al., Oncogene 2005 (Breast Neoplasms) : HDAC inhibitors synergized with TRAIL by inducing DRs DR4/TRAIL-R1 and DR5/TRAIL-R2 through NFkappaB activation and some of the proapoptotic members of the Bcl-2 family, and engaging the mitochondrial pathway
Shetty et al., Mol Cell Biol 2005 (Breast Neoplasms) : Indeed, HDAC inhibitors activate NF-kappaB and p53 and upregulate DR5 expression
Graham et al., Cell cycle (Georgetown, Tex.) 2005 : In addition, HDAC inhibitors induce NFkappaB binding to the DR5 gene and DR5 expression, contributing to HDAC inhibitor induced apoptosis
Chou et al., Mol Immunol 2008 : We have previously reported that Major Histocompatibility Complex ( MHC) class II can be induced by histone deacetylase inhibitors ( HDACi ) in the absence of class II transactivator (CIITA)
Niesen et al., Biol Pharm Bull 2009 (Carcinoma, Non-Small-Cell Lung...) : HDAC inhibitors that can be used to treat patients may augment the expression of tumor cell MHC class II , and the results suggest an opportunity to determine the immunological consequences of HDAC inhibitor treatment in tumor therapy
Bagci-Onder et al., Oncogene 2013 (Glioblastoma) : A histone deacetylase inhibitor, MS-275, resulted in upregulation of DR4/5 in all GBM cell lines, and these changes could be followed in real time both in vitro and in vivo in mice bearing tumors and they correlated with increased TRAIL sensitivity